Characteristic Warfarin

Without Medication Fixed-Mini dose

Warfarin
Number of Patient 50 51

Male 30 29
Gender
Female 20 22

Age (year) 57.50 64.50

Age (group) < 65 38 29

>65 13 21

CHA2DS2-VASc (average) 2.90 2.85

CHA2DS2-VASc (Group) <2 22 20

>2 28 31

HASBLED (average) 2.36 2.33

HASBLED (group) <2 31 38

>2 19 13

Cause of atrial fibrillation Non-Valvular 47 35

Valvular 3 16
Table 1 Baseline characteristic of patient subsequently treated with fixed-mini dose warfarin and
without medication

Warfarin
Without medication Fixed-mini dose warfarin
< 65 years 38 29
Age (group)
>65 years 13 21

Age (avarage) 64.50 57.50

Cause of atrial Non-Valvular 47 35

fibrillation Valvular 3 16

CHA2DS2-VASc (average) 2.90 2.85

No event 44 50
Thromboembolic event
Ischemic stroke 6 1

HASBLED (average) 2.36 2.33

No event 49 50
Bleeding episode
Mayor Bleeding 1 5
 Table 1 Characteristic, thromboembolic event, and bleeding episode of patient subsequently treated
with fixed-mini dose warfarin and without medication

Age (group)
< 65 >65
Thromboembolic event No event 61 (91.2%) 33 (96.97%)
Ischemic stroke 6 (9.80%) 1 (3.03%)
Table 3 Thromboembolic event correlation with age (group)

CHA2DS2-VASc (Group)
<2 >2
Thromboembolic event No event 42 (100%) 52 (86.50%)
Ischemic stroke 0 7 (13.50%)
Table 4 Thromboembolic event correlation with CHA2DS2-VASc (Group)

Odd ratio 6.818 (95%CI, 0.790-58.851)  the result is not significant

The result from Mann-Whitney U test

Test Statisticsa

Stroke

Mann-Whitney U 1147.000
Wilcoxon W 2473.000
Z -1.976
Asymp. Sig. (2-tailed) .048

a. Grouping Variable: Warfarin

This result shows that fixed-mini dose warfarin have a significant effect in preventing
thromboembolic event.